Primary outcome
neurodevelopmental disorder, depression, anxiety, UC
SECONDARY
Unadjusted mean HoNOSCA scores differed significantly between the MT and UC groups at baseline and at 15 months, and declined over time in both groups (online Supplementary Fig. S6). This indicated general improvement in mental health and wellbeing over time in both groups but the reduction appeared more rapid in the MT group (online Supplementary Fig. S7). The difference in mean HoNOSCA scores between the trial arms (MT-UC) at 15 months, estimated by the GLMM, was −1.11 [95% confidence interval (CI) −2.07 to −0.14, Statistical analysis of primary and secondary outcomes 15 months after entry to the studyMean difference in the HoNOSCA score between the trial arms (MT–UC) at 15 months, from a multilevel model with four levels (country, site, participant and follow-up time) and adjustment for gender, baseline HoNOSCA score and diagnosis (categorised as anxiety, depression, neurodevelopmental disorder or other).Mean difference in HoNOSCA-SR score between the trial arms (MT–UC) at 15 months, from a multilevel model with four levels (country, site, participant and follow-up time) and adjustment for gender, baseline HoNOSCA-SR score and diagnosis (categorised as anxiety, depression, neurodevelopmental disorder or other).Mean difference in WHOQOL-BREF score between the trial arms (MT–UC) at 15 months, from a multilevel model with four levels (country, site, participant and follow-up time) and adjustment for gender, baseline WHOQOL-BREF score and diagnosis (categorised as anxiety, depression, neurodevelopmental disorder or other).